Reports FY24 revenue $25.3M, consensus $25.15M. “We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million2024 year ...

In this article, we are going to take a look at where Invivyd, Inc. (NASDAQ:IVVD) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in ...

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago. These figures are ...

NASDAQ:IVVD opened at $1.01 on Wednesday. The business has a 50 day moving average of $0.92 and a 200 day moving average of $0.88. The company has a market capitalization of $120.81 million, a ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Invivyd, Inc. (NASDAQ:IVVD) stands against ...

Shares of IVVD stock opened at $1.30 on Monday. The business’s 50 day moving average is $0.82 and its two-hundred day moving average is $0.87. Invivyd has a twelve month low of $0.35 and a ...

In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Invivyd (IVVD – Research Report), with a price target of $10.00. The company’s shares closed ...

2; affirms structural biology within Invivyd’s unique technology and reflects consi Invivyd (NasdaqGM:IVVD) has seen its share price surge by an impressive 163% over the past month, driven primarily ...

Detailed price information for Invivyd Inc (IVVD-Q) from The Globe and Mail including charting and trades.